Cousin F, Jouan Lanhouet S, Théret N, Brenner C, Jouan E, Le Moigne Muller G, et al. The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer. Oncotarget. 2016;7:7161-78 pubmed publisher

Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577 pubmed publisher

Green A, Caracappa D, Benhasouna A, Alshareeda A, Nolan C, Macmillan R, et al. Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Res Treat. 2015;149:353-62 pubmed publisher

Del Mistro G, Lucarelli P, Muller I, de Landtsheer S, Zinoveva A, Hutt M, et al. Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma. NPJ Syst Biol Appl. 2018;4:39 pubmed publisher

Srivastava S, Mohibi S, Mirza S, Band H, Band V. Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway. Cell Cycle. 2017;16:1515-1525 pubmed publisher

Sato Y, Inoue M, Yoshizawa T, Yamagata K. Moderate hypoxia induces β-cell dysfunction with HIF-1-independent gene expression changes. PLoS ONE. 2014;9:e114868 pubmed publisher

Müller I, Beissert S, Kulms D. Anti-apoptotic NF-κB and "gain of function" mutp53 in concert act pro-apoptotic in response to UVB+IL-1 via enhanced TNF production. J Invest Dermatol. 2015;135:851-860 pubmed publisher